AMENDMENTS

Please amend the claims as follows:

Please cancel claims 21-23, 26 and 30-32.

Claims 1-26 (Canceled).

Claims 28-32 (Canceled).

Please add the following new claims:

33. (New) A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:

(a) obtaining a sample from said individual;

(b) measuring a test expression level of PAMP polypeptide by contacting a cell, a cell lysate, or fractionated sample thereof, from said individual with a binding agent selective for residues 1 to 1074 of a PAMP polypeptide comprising the amino acid sequence shown as SEQ ID NO: 2, and determining the amount of selective binding of said agent; and

(c) comparing said test expression level of PAMP polypeptide to a control expression level of PAMP polypeptide,

wherein a test expression level significantly greater than said control expression level indicates the presence of a prostate neoplastic condition.

34. (New) The method of claim 33, wherein said binding agent comprises an antibody.

35. (New) The method of claim 33, wherein said binding agent further comprises a detectable label.

36. (New) The method of claim 33, wherein said binding agent is a monoclonal antibody.

37. (New) The method of claim 33, wherein said binding agent is a polyclonal antibody.

38. (New) The method of claim 33, wherein said sample is a serum sample.

39. (New) The method of claim 33, wherein said sample is a blood sample.

40. (New) An isolated PAMP polypeptide, comprising an amino acid sequence having 50% or more identity to SEQ ID NO:2.

41. (New) The isolated PAMP polypeptide of claim 40, wherein said amino acid sequence has 55% or more identity to SEQ ID NO:2.

42. (New) The isolated PAMP polypeptide of claim 40, wherein said amino acid sequence has 60% or more identity to SEQ ID NO:2.

43. (New) The isolated PAMP polypeptide of claim 40, wherein said amino acid sequence has 65% or more identity to SEQ ID NO:2.

44. (New) The isolated PAMP polypeptide of claim 40, wherein said amino acid sequence has 70% or more identity to SEQ ID NO:2.

45. (New) The isolated PAMP polypeptide of claim 40, wherein said amino acid sequence has 75% or more identity to SEQ ID NO:2.

46. (New) The isolated PAMP polypeptide of claim 40, wherein said amino acid sequence has 80% or more identity to SEQ ID NO:2.

47. (New) The isolated PAMP polypeptide of claim 40, wherein said amino acid sequence has 85% or more identity to SEQ ID NO:2.

48. (New) The isolated PAMP polypeptide of claim 40, wherein said amino acid sequence has 90% or more identity to SEQ ID NO:2.

49. (New) The isolated PAMP polypeptide of claim 40, wherein said amino acid sequence has 95% or more identity to SEQ ID NO:2.

50. (New) A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:

(a) obtaining a sample from said individual;

(b) measuring a test expression level of PAMP polypeptide by contacting a cell, a cell lysate, or fractionated sample thereof, from said individual with a binding agent selective for residues 1 to 1074 of a PAMP polypeptide comprising an amino acid sequence having at least 50% identity to SEQ ID NO: 2, and determining the amount of selective binding of said agent; and

(c) comparing said test expression level of PAMP polypeptide to a control expression level of PAMP polypeptide,

wherein a test expression level significantly greater than said control expression level indicates the presence of a prostate neoplastic condition.

51. (New) The method of claim 50, wherein said binding agent comprises an antibody.

52. (New) The method of claim 50, wherein said binding agent further comprises a detectable label.

53. (New) The method of claim 50, wherein said binding agent is a monoclonal antibody.

54. (New) The method of claim 50, wherein said binding agent is a polyclonal antibody.

55. (New) The method of claim 50, wherein said sample is a serum sample.

56. (New) The method of claim 50, wherein said sample is a blood sample.

57. (New) The method of claim 50, wherein said amino acid sequence has 55% or more identity to SEQ ID NO:2.

58. (New) The method of claim 50, wherein said amino acid sequence has 60% or more identity to SEQ ID NO:2.

59. (New) The method of claim 50, wherein said amino acid sequence has 65% or more identity to SEQ ID NO:2.

60. (New) The method of claim 50, wherein said amino acid sequence has 70% or more identity to SEQ ID NO:2.

61. (New) The method of claim 50, wherein said amino acid sequence has 75% or more identity to SEQ ID NO:2.

62. (New) The method of claim 50, wherein said amino acid sequence has 80% or more identity to SEQ ID NO:2.

63. (New) The method of claim 50, wherein said amino acid sequence has 85% or more identity to SEQ ID NO:2.

64. (New) The method of claim 50, wherein said amino acid sequence has 90% or more identity to SEQ ID NO:2.

65. (New) The method of claim 50, wherein said amino acid sequence has 95% or more identity to SEQ ID NO:2.